Clinical Trial News and Research

RSS

Third-quarter 2009 financial results announced by Inhibitex

Inhibitex, Inc., today announced its financial results for the third quarter ended September 30, 2009. The Company held cash, cash equivalents and short-term investments of $21.1 million at September 30, 2009, as compared to $33.1 million at December 31, 2008.

6 Nov 2009

Bioniche Life Sciences announces financial results for its Fiscal 2010 first-quarter

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 first quarter, ended September 30, 2009.

6 Nov 2009

Landmark meeting discusses goal of detecting Alzheimer disease before symptoms appear

This past October, 214 researchers from the U.S., Europe, and Australia, as well as representatives of families with aggressive genetic forms of Alzheimer disease (AD), met at Washington University, St. Louis, Missouri, to devote two intense days of talks and discussion to their goal of detecting this disease before symptoms appear. By a growing consensus, defining the "silent" phase of AD has become the field's central challenge if it is to modernize drug testing and lay the groundwork for AD prevention trials.

6 Nov 2009

Novexel commences comparative study of NXL103 to oral linezolid

Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI). The trial is designed to assess the safety and efficacy of NXL103 in comparison to oral linezolid.

6 Nov 2009

Results of LightTouch Non-invasive Cervical Cancer Detection Device trial presented

Results of the FDA pivotal clinical trial for the LightTouch™ Non-invasive Cervical Cancer Detection Device conducted by Guided Therapeutics, Inc. (GT), indicated that the current system for diagnosing cervical disease missed the same amount of disease as a landmark study carried out by the National Cancer Institute (NCI).

6 Nov 2009

Quintiles opens expanded regional headquarters facility in Singapore

To meet the growing demand for its services throughout the Asia-Pacific region, Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today announced the official grand opening of its expanded regional headquarters facility in Singapore’s Science Park I.

6 Nov 2009

Catalent Pharma Solutions, Endotis Pharma forge alliance to develop oral formulations of small-glycol drugs

Catalent Pharma Solutions, the leading provider of advanced oral drug delivery technologies to the pharmaceutical industry, has entered into a strategic alliance with Endotis Pharma for the development of oral formulations of synthetic oligosaccharides.

5 Nov 2009

Abraxis BioScience reports $96.6 million net revenues for third quarter of 2009

Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the third quarter ending September 30, 2009.

5 Nov 2009

ARIAD Pharmaceuticals' SUCCEED trial of oral ridaforolimus on track

ARIAD Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009 and provided an update on corporate developments.

5 Nov 2009

Oncolytics Biotech reports financial results for the third quarter of 2009

Oncolytics Biotech Inc. today announced its financial results for the three and nine-month periods ended September 30, 2009.

5 Nov 2009

ArQule reports financial results for the fiscal quarter and nine months ended September 30, 2009

ArQule, Inc. today reported its results of operations for the fiscal quarter and nine months ended September 30, 2009.

5 Nov 2009

Inspire Pharmaceuticals reports net loss of $8.5 million for the third quarter ended September 30, 2009

Inspire Pharmaceuticals, Inc. announced today financial results for the third quarter ended September 30, 2009, reporting a net loss of $8.5 million or ($0.12) per common share.

5 Nov 2009

Atrium Medical presents final results of its "COCTAIL study"

Atrium Medical Corporation is proud to announce the release of the final results of the "COCTAIL Study," a clinical study comparing local administration of an anti-platelet medication with the company's proprietary infusion balloon technology.

5 Nov 2009

Second-quarter fiscal 2010 results announced by Repligen

Repligen Corporation today reported results for the second quarter of fiscal year 2010, ended September 30, 2009. Total revenue for the quarter was $5,421,000 compared to total revenue of $5,090,000 for the second quarter of fiscal year 2009 ended September 30, 2008.

5 Nov 2009

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that mediate RNAi.

5 Nov 2009

Columbia Laboratories reports net revenues of $7.9 million for third quarter 2009

Columbia Laboratories, Inc. today reported financial results for the three- and nine-month periods ended September 30, 2009.

5 Nov 2009

Evidence continues to grow about green tea's cancer prevention properties

Although scientists are reluctant to officially endorse green tea as a cancer prevention method, evidence continues to grow about its protective effects, including results of a new study published in Cancer Prevention Research, a journal of the American Association for Cancer Research, which suggests some reduction in oral cancer.

5 Nov 2009

Study demonstrates potential of human Serum Amyloid P to block very aggressive fibrotic pathology

Promedior, Inc., a leader in the development of novel therapeutics for the treatment of fibrotic diseases and tissue remodeling, announced today the publication of results from preclinical studies demonstrating that human Serum Amyloid P (hSAP) potently inhibited fibrosis in two independent model systems of kidney fibrosis.

5 Nov 2009

Raptor Pharmaceutical to present oral AMPA-kainate antagonist data at the neuropathic pain conference

Raptor Pharmaceutical Corp., today announced that data from a clinical trial of NGX426, the Company's orally administered non-opioid, AMPA/kainate antagonist, will be presented at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, to be held November 20-21, 2009 in San Francisco.

5 Nov 2009

Patient enrollment in three late-stage clinical trials completed

Inspire Pharmaceuticals, Inc. announced today patient enrollment is complete in three of its late-stage clinical trials.

5 Nov 2009

Clinical Trial News and Research

Third-quarter 2009 financial results announced by Inhibitex

Bioniche Life Sciences announces financial results for its Fiscal 2010 first-quarter

Landmark meeting discusses goal of detecting Alzheimer disease before symptoms appear

Novexel commences comparative study of NXL103 to oral linezolid

Results of LightTouch Non-invasive Cervical Cancer Detection Device trial presented

Quintiles opens expanded regional headquarters facility in Singapore

Catalent Pharma Solutions, Endotis Pharma forge alliance to develop oral formulations of small-glycol drugs

Abraxis BioScience reports $96.6 million net revenues for third quarter of 2009

ARIAD Pharmaceuticals' SUCCEED trial of oral ridaforolimus on track

Oncolytics Biotech reports financial results for the third quarter of 2009

ArQule reports financial results for the fiscal quarter and nine months ended September 30, 2009

Inspire Pharmaceuticals reports net loss of $8.5 million for the third quarter ended September 30, 2009

Atrium Medical presents final results of its "COCTAIL study"

Second-quarter fiscal 2010 results announced by Repligen

Alnylam Pharmaceuticals presents new data related to its overall delivery research efforts

Columbia Laboratories reports net revenues of $7.9 million for third quarter 2009

Evidence continues to grow about green tea's cancer prevention properties

Study demonstrates potential of human Serum Amyloid P to block very aggressive fibrotic pathology

Raptor Pharmaceutical to present oral AMPA-kainate antagonist data at the neuropathic pain conference

Patient enrollment in three late-stage clinical trials completed

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News